As of mid-2025, the FDA’s official review timelines for medical device submissions are still holding—for now. That’s good news for startups navigating premarket pathways. But under the surface, structural pressures and staffing cuts could begin to affect review speed, predictability, and program availability—especially in digital health.

If you’re preparing a 510(k), De Novo, or PMA submission, this post walks through:

• Where review timelines stand now
  
• Why we haven’t seen major delays yet
  
• Which programs are most vulnerable
  
• What digital health teams should do to stay on track

What’s Holding Steady?

Despite headlines and layoffs, statutory FDA review timelines are currently being honored for key submission types:

These timelines reflect the number of review days in FDA’s hands—not counting time paused due to Requests for Additional Information (RAIs), which are increasingly common.

Why Haven’t Timelines Collapsed (Yet)?

So far, several interventions have kept the system afloat:

• Industry advocacy—notably by AdvaMed and others—prompted the administration to rescind layoff notices for key FDA reviewers.
• The return-to-office mandate was rolled back to retain existing staff and slow attrition.
• The agency is piloting AI-assisted scientific reviews—which could eventually speed up processing by reducing manual reviewer burden.

These efforts have bought the FDA some time—but the pressure is still building, especially in specialized areas like AI/ML, radiology, and imaging.

Where Are Delays Most Likely?

While core timelines are holding, the cracks are showing in high-expertise and resource-dependent areas.

• Subject matter experts (SMEs)—especially in AI, imaging, and digital health—have been among the hardest hit by FDA’s staffing cuts.
• Administrative support and communications offices have also seen reductions, which can delay informal feedback or status updates.
• For startups building in software-heavy fields, this may mean more RAIs, slower reviewer responses, and fewer touchpoints.

In short: the FDA’s “white glove” approach to complex submissions may be harder to access in 2025.

What About Optional FDA Programs?

Programs the FDA offers on a “resources permitting” basis are the most likely to slow or pause.

These include:

• Q-Sub (Pre-Submission) meetings
• Breakthrough Device designation reviews
• Iterative review cycles

If your startup has benefited from Q-Subs or collaborative feedback loops in the past, you may notice reduced availability or delayed scheduling.

Tips for Device Developers Navigating This Landscape

Here’s how startups can proactively adapt to a more strained review environment:

1. Use Third-Party Accredited Reviewers (for 510(k), where eligible)

FDA-authorized third parties can conduct primary reviews of certain Class II devices. This pathway may become more attractive as internal FDA resources tighten—especially for “cookie-cutter” 510(k)s with clear predicates.

→ Check FDA’s list of accredited third-party reviewers.

2. Make Your Submission Easy to Review

This is not the year to get creative or overly nuanced.

• Stick to clear comparisons and established frameworks.
• Avoid logic-heavy arguments that rely on SME interpretation—your reviewer may be new, overloaded, or missing a second set of eyes.
• Follow FDA guidance documents and accepted standards exactly.

Goal: Make your submission reviewable in a single pass by someone unfamiliar with your tech.

3. Keep Q-Sub Requests Short and Targeted

If you do request a Pre-Sub meeting:

• Ask only 1–2 specific questions
• Make your request concise and clearly scoped
• Consider requesting a live meeting for faster, real-time clarification

This increases the chances of getting timely, actionable feedback—especially as reviewer bandwidth tightens.

4. Include a PCCP in Your Submission

A Predetermined Change Control Plan (PCCP) outlines post-market modifications your device might undergo (e.g., software updates, algorithm improvements).

If approved, you can implement those changes without a full resubmission—a major advantage if the agency slows down further.

This is especially useful for AI-driven or adaptive tools expected to evolve post-market.

Final Thoughts: Be Proactive, Not Passive

While formal timelines are mostly holding, 2025 is shaping up to be a year where the informal systems founders rely on—feedback meetings, SME guidance, reviewer responsiveness—may be constrained.

If you’re building an AI or digital health product:

• Build margin into your launch and fundraising timelines
• Watch for signals about reviewer feedback slowdowns
• Prioritize clarity, compliance, and predictability over novelty

And if you have insights of your own from recent FDA interactions—please share them. The more we collaborate, the better we can adapt.